![In 3-day marathon, ODAC winnows “dangling” accelerated approvals of PD-1/PD-L1 drugs](https://cdn.cancerletter.com/media/2021/04/30143040/47-17-dangling-4x3-1.jpg)
![In 3-day marathon, ODAC winnows “dangling” accelerated approvals of PD-1/PD-L1 drugs](https://cdn.cancerletter.com/media/2021/04/30143040/47-17-dangling-4x3-1.jpg)
Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Chernobyl: a 35 year follow up on long-term health effects
- Suspensions, public outrage ensue as tensions over Middle East sweep through oncology
NYU Cancer Center Director Benjamin Neel suspended over social media posts - What are you reading in 2024?
- Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored
Three reprimands later, he retains leadership—and mentorship—positions